Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Journal of Chinese Physician ; (12): 6-10, 2023.
Article in Chinese | WPRIM | ID: wpr-992252

ABSTRACT

Objective:To explore the changes of immune microenvironment and prognosis of bladder cancer patients with positive urinary nuclear matrix protein 22 (NMP22).Methods:Retrospective analysis was made on 86 patients who were diagnosed with bladder cancer in Xuzhou Central Hospital from January 2019 to September 2020. All patients were tested for urinary NMP22 by colloidal gold method. The patients with positive test results were NMP22 positive group, and the patients with negative test results were NMP22 negative group. The expression of CD8, programmed cell death-ligand 1 (PD-L1), programmed cell death protein-1 (PD-1) and PanCK were detected by multiple fluorescent immunohistochemical method on the pathological tissue sections of all enrolled patients with bladder cancer after surgery. Follow-up data of enrolled patients were collected after discharge, and univariate and multivariate Cox analysis was performed on the follow-up data.Results:There were 69 patients in the NMP22 positive group and 17 patients in the NMP22 negative group. The percentage of CD8 and PD-L1 positive cells in NMP22 positive group was significantly higher than that in NMP22 negative group, and the difference was statistically significant (all P<0.05). Univariate analysis showed that tumor stage was correlated with bladder cancer progression ( HR=2.67, P=0.017). Multivariate analysis showed that positive NMP22 was significantly correlated with bladder cancer recurrence and disease progression (all P<0.05). Conclusions:The density of CD8 + T cells and PD-L1 in tumor parenchyma of urinary NMP22 positive bladder cancer patients was higher than that of NMP22 negative patients. Urinary NMP22 positive can be one of the bad prognostic factors of bladder cancer, and the patients with NMP22 positive should strengthen reexamination.

2.
Article | IMSEAR | ID: sea-225523

ABSTRACT

The chromosomal abnormality of Philadelphia chromosome is mostly seen in Chronic Myeloid Leukemia (CML). But it is observed that the Philadelphia chromosome (Ph), t(9,22), is the most common cytogenetic abnormality in adult patients with acute lymphoblastic leukemia (ALL), occurring in about 20% to 30 % of all cases. Patients with Ph-positive ALL have breaks in the minor breakpoint region, m?BCR (exons 1?2) lead to a short fusion proteins (p190) and is most frequently associated with Ph chromosome- positive ALL. They have an increased risk for central nervous system (CNS) involvement, an aggressive clinical course and poor prognosis. Historically, they had an inferior outcome when compared with their Ph-negative counterparts. Adult Ph+ patients achieve Complete Remission rates comparable to Ph? ALL patients with standard chemotherapy, but the remissions are short and survival poor. The addition of tyrosine kinase inhibitors (TKIs) including imatinib has dramatically improved outcomes. We are presenting this case report of t(9;22), p190 BCR-ABL1 positive ALL in an elderly female patient of south Gujarat.

3.
Chinese Journal of Oncology ; (12): 260-267, 2022.
Article in Chinese | WPRIM | ID: wpr-935209

ABSTRACT

Objective: To investigate the expression of programmed death ligand-1 (PD-L1, SP142) and PD-L1 (22C3) in triple-negative breast cancer (TNBC), and analyze their correlation with the clinicopathological factors and prognosis. Methods: The clinicopathologic data of 259 patients with TNBC treated in Cancer Hospital from August 2010 to December 2013 were collected. Whole section of surgical tissue samples were collected to conduct PD-L1 (SP142) and PD-L1 (22C3) immunohistochemical (IHC) staining. The PD-L1 expression in tumor cells and tumor infiltrating immune cells were visually assessed respectively, the relationship between PD-L1 expression and clinicopathologic characterizes were analyzed. Univariable and multivariable Cox proportional hazards regression models were used to test the correlations between PD-L1 expression and disease-free survival (DFS) and overall survival (OS). Results: The positive rates of SP142 (immune cell score, ICs≥1%) and 22C3 (combined positive score, CPS≥1) were 42.1%(109/259) and 41.3%(107/259) in TNBC tissues, respectively, with a total coincidence rate of 82.3%. The Kappa value of positive expression cases was 0.571 and the distribution difference of SP142 and 22C3 positive expression cases was statistically significant (P<0.001). The PD-L1 positive patients were less likely to have vascular invasion (P<0.05), but with higher histological grade and Ki-67 proliferation index (P<0.05). The recurrence/metastasis cases(8) of the patients with positive PD-L1 (SP142) was significantly lower than that of patients with negative PD-L1(SP142, 27, P=0.016). The positive expression of PD-L1 (SP142) patients were longer DFS (P=0.019). The OS of patients with positive PD-L1 (SP142) were longer than those with negative PD-L1 (SP142), but without significance (P=0.116). The positive expression of PD-L1 (22C3) was marginally associated with DFS and OS of patients (P>0.05). Conclusions: The expression of PD-L1 (22C3) is different from that of PD-L1 (SP142) in TNBC, and the two antibodies can't be interchangeable for each other in clinical tests. PD-L1 (SP142) status is an independent prognostic factor of DFS in TNBC. The DFS is significantly prolonged in patients with positive expression of PD-L1 (SP142).


Subject(s)
Humans , B7-H1 Antigen/genetics , Immunohistochemistry , Prognosis , Triple Negative Breast Neoplasms/pathology
4.
Journal of Experimental Hematology ; (6): 367-372, 2022.
Article in Chinese | WPRIM | ID: wpr-928722

ABSTRACT

OBJECTIVE@#To summarize the clinical and laboratory characteristics of patients with acute myeloid leukemia (AML) with inv(16)/t(16;16) (p13.1;q22), and to analyze the risk factors affecting the prognosis of the patients.@*METHODS@#AML patients with inv(16)/t(16;16) (p13.1;q22) and/or CBFβ-MYH11+ admitted to the Department of Hematology, The First Affiliated Hospital of Soochow University from January 1, 2008 to October 30, 2019 were retrospective analyzed, the clinical and laboratory indicators, as well as treatment plans and efficacy evaluations of the patients were all recorded. Furthermore, related factors affecting the overall survival (OS) and event-free survival (EFS) of the patients were analyzed.@*RESULTS@#Among 151 AML patients with inv(16)/t(16;16) (p13.1;q22) and/or CBFβ-MYH11+, the percentage of additional chromosomal abnormalities was about 27.8%, and the most common additional chromosomal abnormality was +22 (33/151, 21.8%), followed by +8 (11/151, 7.3%). There were 112 patients with perfect NGS examination, and the result showed the most common accompanying gene mutations were KIT mutation (34/112, 30.4%) and FLT3 mutation (23/112, 20.5%). Univariate analysis showed that factors affecting EFS included: NE≤0.5×109/L (P=0.006) and combined K-RAS mutation (P=0.002); Factors affecting OS included: Age≥50 years old (P<0.001) and NE≤0.5×109/L (P=0.016). Multivariate analysis showed that NE≤0.5×109/L (P=0.019) was the risk factors affecting OS. The proportion of bone marrow eosinophilia (BME)≥10.00% (P=0.029) was the risk factors affecting EFS.@*CONCLUSION@#The prognosis for those newly diagnosed AML patients who were of advanced age, the high proportion of bone marrow eosinophils, K-RAS mutations, and agranulocytosis is poor. The treatment plans can be adjusted in the early stage to improve the prognosis of such patients.


Subject(s)
Humans , Middle Aged , Chromosome Inversion , Leukemia, Myeloid, Acute/genetics , Myosin Heavy Chains/genetics , Oncogene Proteins, Fusion , Prognosis , Retrospective Studies
5.
Frontiers of Medicine ; (4): 608-620, 2021.
Article in English | WPRIM | ID: wpr-888743

ABSTRACT

t(8;21)(q22;q22) acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy with a high relapse rate in China. Two leukemic myeloblast populations (CD34


Subject(s)
Humans , Gene Expression , Granulocyte Precursor Cells , Immunophenotyping , Leukemia, Myeloid, Acute/genetics , Membrane Glycoproteins , Prognosis , Proteins , Proto-Oncogene Proteins c-kit/genetics
6.
Journal of Medical Research ; (12): 161-163,187, 2018.
Article in Chinese | WPRIM | ID: wpr-700956

ABSTRACT

Objective To investigate the clinical significance of peripheral blood T-helper (Th22) cells in assessing the severity and prognosis of patients with sepsis.Methods A total of 220 patients with sepsis in our hospital from January 2013 to January 2017 were enrolled in the study.According to the severity of sepsis,these patients were divided into low risk group (84 cases),middle risk group (74 cases) and high risk group (62 cases).According to the clinical outcome of sepsis,these patients were divided into survival group (195 cases) and death group (25 cases).The levels of Th22 cells,IL-22 and CRP in the peripheral blood were measured,and the acute physiology and chronic health status (APACHE Ⅱ) score were recorded,the predictive value of peripheral blood Th22 cells in deathof sepsis was assessed by the receiver operating characteristic curve (ROC).Results The levels of Th22 cells,IL-22 and APACHE Ⅱ in the low-risk group,the intermediate-risk group and the high-risk group were statistically significant (P < 0.05).The high-risk group was highest,followed by the intermediate-risk group,the low-risk group was lowest among them.The levels of Th22,IL-22 and APACHE Ⅱ scores of the death group were significantly higher than those in the survival group (P < 0.05).The correlation analysis showed that the Th22 celss in peripheral blood were positively correlated with IL-22 (r =0.70,P < 0.01) and APACHE Ⅱ scores (r =0.75,P < 0.01).When Th22 cells in peripheral blood > 3.3% for the assessing the poor prognosis of sepsis boundaries,the sensitivity and specificity were 84.4% and 86.1%.Conclusion The Th22 cells in peripheral blood and IL-22 are closely related to the severity and prognosis of sepsis,serving as an assessing index and have important clinical value.

7.
Korean Journal of Clinical Pathology ; : 337-341, 1999.
Article in Korean | WPRIM | ID: wpr-228753

ABSTRACT

BACKGROUND: CD22 is a glycoprotein expressed on the surface of normal mature B cells and in the cytoplasm of normal B cell precursors. Cytoplasmic CD22 (cCD22) has been proposed as a immunologic marker for the diagnosis of B-lineage acute lymphoblastic leukemia (ALL) while membrane CD22 (mCD22) has been used as the marker for chronic lymphocytic leukemia, B-lineage lymphoma, and hairly cell leukemia, and mCD22 has not been routinely used for the diagnosis and subgrouping of ALL. The purpose of this study was to examine the expression of mCD22 in B-lineage ALL and its clinical significance. METHODS: From 1992 to April, 1998, the leukemic cells of 64 patients newly diagnosed as B-lineage ALL by immunophenotyping were analyzed by the direct immunofluorescence method using monoclonal antibodies including mCD22. RESULTS: mCD22 was positive in 53% (34/64) of all patients, 50% (21/42) of children and 59% (13/22) of adults. According to the immunologic classification, mCD22 was positive in 44% (4/9) of group II, 53% (19/36) of group III, 69% (11/16) of group IV, but negative in 3 cases of group V and VI. The complete remission rate of the mCD22 negative group in group III was significantly higher than that of the mCD22 positive group (P=0.008). There were significant differences in survival rates between the mCD22 positive group and the mCD22 negative group in group II, III and IV (P=0.046) and the above observed significant difference was seen when group III was separately tested (P=0.014). CONCLUSIONS: Our study demonstrated that the expression of mCD22 may be a poor prognostic factor in B-lineage ALL and that mCD22 shall be clinically used as a prognostic marker especially in group III, which is most common among the subgroups of B-lineage ALL.


Subject(s)
Adult , Child , Humans , Antibodies, Monoclonal , B-Lymphocytes , Biomarkers , Classification , Cytoplasm , Diagnosis , Fluorescent Antibody Technique, Direct , Glycoproteins , Immunophenotyping , Leukemia , Leukemia, Lymphocytic, Chronic, B-Cell , Lymphoma , Membranes , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Prognosis , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL